Low-Dose Nivolumab Shows Responses in Retrospective Nepal Cancer Cohort
A retrospective Nepalese cohort of 31 patients associated 20- or 40-milligram nivolumab with responses across advanced cancers, but uncontrolled evidence ...
Tag: PD-1 inhibitor
Cancer Immunotherapy Unmasks Rare Myasthenia Gravis Twelve Years After Thymectomy
A case report describes pembrolizumab-induced myasthenia gravis with isolated anti-titin antibody positivity in a man twelve years after thymectomy for ...
Immunotherapy Before Standard Treatment Shows Striking Results in Nasopharyngeal Cancer
A prospective Chinese study found that adding the immunotherapy drug camrelizumab to induction chemotherapy before concurrent chemoradiotherapy produced high complete ...
Triple Therapy Doubles Survival in Advanced Liver Cancer with Portal Vein Clots
A prospective controlled study in BMC Medicine found that adding hepatic arterial infusion chemotherapy to lenvatinib and a PD-1 inhibitor ...
Immunotherapy Added to Standard Treatment Shows Early Promise Against Aggressive Brain Tumors
A retrospective study of 25 patients suggests that adding the anti-PD-1 antibody pucotenlimab to concurrent radiochemotherapy produced tumor responses and ...
Immunotherapy Boost for Bile Duct Cancer Survival Holds Firm After Three Years
Three-year follow-up of the phase 3 KEYNOTE-966 trial confirms that adding pembrolizumab to gemcitabine and cisplatin chemotherapy maintains a durable ...
Chemoimmunotherapy Before Surgery Lets Some Head and Neck Cancer Patients Skip High-Dose Radiation
A phase II trial found that preoperative chemo-immunotherapy with sintilimab achieved major pathological responses in 59.1 percent of locally advanced ...
Adding Immunotherapy to Chemo and Bevacizumab Extends Survival in Recurrent Cervical Cancer
A retrospective Chinese study finds that adding the PD-1 inhibitor tislelizumab to paclitaxel-carboplatin chemotherapy and bevacizumab significantly improves response rates, ...
Immunotherapy Before Surgery: Sintilimab Helps Shrink Advanced Ovarian Cancer in Landmark Case
A case report describes advanced ovarian cancer shrinking dramatically after the PD-1 inhibitor sintilimab was added to chemotherapy, enabling complete ...
Immunotherapy After Surgery Shows Durable Results in High-Risk Esophageal Cancer
A phase II trial found that adjuvant sintilimab monotherapy after surgery met its primary efficacy endpoint with 87.5 percent one-year ...
-
Mothers who receive childcare support from maternal grandparents show more parental warmth, finds NTU Singapore study
-
University of Seville Breaks 120-Year-Old Mystery, Revises a Key Einstein Concept
-
Bee body mass, pathogens and local climate influence heat tolerance
-
Researchers record first-ever images and data of a shark experiencing a boat strike
-
Groundbreaking Clinical Trial Reveals Lubiprostone Enhances Kidney Function
Embark on a thrilling journey of discovery with Scienmag.com—your ultimate source for cutting-edge breakthroughs. Immerse yourself in a world where curiosity knows no limits and tomorrow’s possibilities become today’s reality!